| |
|
|
|
|
|
 |
| |
|
ÇǶó¸°ÁÖ [Diphenylpyraline HCl]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
[A02751221]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1ml/¾ÚÇÃ(2007.03.01)(ÇöÀç¾à°¡)
\163 ¿ø/1ml/¾ÚÇÃ(2003.05.02)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»öÅõ¸íÇÑ ¾×À» ÃæÁøÇÑ ¹«»öÅõ¸íÇÑ ¾ÚÇà [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1¾ÚÇÃ(1¹Ð¸®¸®ÅÍ) X ÀÚ»çÆ÷Àå´ÜÀ§ |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¢º È¿´ÉÈ¿°ú
(°æ±¸: »êÁ¦)
µÎµå·¯±â, ¾Ë·¹¸£±â¼º ºñ¿°, ÄÚ°¨±â·ÎÀÎÇÑ Àçä±âÄ๰±âħ, °íÃÊ¿, ¼Ò¾ç¼ºÇǺÎÁúȯ (½ÀÁøÇǺο°, ÇǺμҾçÁõ, ¾àÁø, Áßµ¶Áø)
(ÁÖ»çÁ¦)
µÎµå·¯±â, ¾Ë·¹¸£±â¼º ºñ¿°, ÄÚ°¨±â·Î ÀÎÇÑ Àçä±âÄ๰±âħ, ¼Ò¾ç¼º ÇǺÎÁúȯ(½ÀÁøÇǺο°, ÇǺμҾçÁõ, ¾àÁø, Áßµ¶Áø)
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:146901BIJ ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¢º ¿ë¹ý¿ë·®
(°æ±¸ : »êÁ¦)
¼ºÀÎ : ¿°»êµðÆä´ÒÇǶó¸°À¸·Î¼ 1ȸ 2-4mg 1ÀÏ 3-4ȸ °æ±¸Åõ¿©ÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
(ÁÖ»çÁ¦)
¼ºÀÎ : ¿°»êµðÆä´ÒÇǶó¸°À¸·Î¼ 1ȸ 2-4mg 1ÀÏ 1-2ȸ ÇÇÇÏ ¶Ç´Â ±ÙÀ° ÁÖ»çÇÑ´Ù.
¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
|
| ±Ý±â |
1) ³ì³»Àå ȯÀÚ(Ç×Äݸ°ÀÛ¿ë¿¡ ÀÇÇØ ¾È¾ÐÀÌ »ó½ÂÇÒ ¼ö ÀÖ´Ù.)
2) Àü¸³¼±ºñ´ë µî ÇϺοä·ÎÆó¼âÁúȯ ȯÀÚ(Ç×Äݸ° ÀÛ¿ë¿¡ ÀÇÇØ ¹è´¢°ï¶õ, ¿äÆó µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
3) ÀÌ ¾àÀÇ ¼ººÐ¿¡ ´ëÇÑ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
|
| ÀÌ»ó¹ÝÀÀ |
1) Á¤½Å½Å°æ°è :±Çۨ, ¾îÁö·¯¿ò, ½Å°æ°ú¹Î, ¶§¶§·Î Á¹À½, µÎÅëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
2) ¼Òȱâ°è : ±¸°¥, ±¸¿ª, ±¸Åä, ½Ä¿åºÎÁø, ¼³»ç, º¯ºñ µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
3) ºñ´¢±â°è : ¹è´¢°ï¶õÀ̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
4) È£Èí±â°è : °´´ã¹èÃâ°ï¶õÀ̳ªÅ¸³¯ ¼ö ÀÖ´Ù.
5) °ú¹ÎÁõ : ¹ßÁøµîÀÌ ³ªÅ¸³ª´Â °æ¿ì´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
6) ¼ï, ¾Æ³ªÇʶô½Ã¾çÁõ»ó : ¼ï(ÀǽļҽÇ, Ç÷¾ÐÀúÇϵî), ¾Æ³ªÇʶô½Ã¾ç Áõ»ó(¹ßÇÑ, ±¸ Åä, ¾È¸éâ¹é, µÎµå·¯±â µî)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î °üÂûÀ» ÃæºÐÈ÷ Çϰí ÀÌ»óÀÌ ³ª Ÿ³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇϰųª, ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
|
| »óÈ£ÀÛ¿ë |
ÁßÃ߽Űæ¾ïÁ¦Á¦(¹Ù¸£ºñÅ»°èÀ¯µµÃ¼, Æä³ëÄ¡¾ÆÁø À¯µµÃ¼, ¾ËÄÚ¿Ã), MAO ¾ïÁ¦Á¦¿ÍÀÇ º´¿ë¿¡ ÀÇÇØ »óÈ£ÀÛ¿ëÀ» Áõ°½Ãų ¼ö ÀÖÀ¸¹Ç·Î º´¿ë½Ã°¨·®ÇÏ´Â µî ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù.
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: DIPHENYLPYRALINE HYDROCHLORIDEHISPRIL (DIPHENYLPYRALINE HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¹¾à¶óº§ |
| À̹ÌÁö |
º¹¾à¼³¸í |
 |
º¯ºñ°¡ »ý±æ¼ö ÀÖ½À´Ï´Ù. |
|
 |
¾îÁö·¯¿òÀÌ ÀÖÀ»¼ö ÀÖ½À´Ï´Ù. |
|
|
| * |
º¹¾àÀ̹ÌÁö´Â ¸ðµç º¹¾àÁöµµ »çÇ×À» Ç¥½ÃÇѰÍÀº ¾Æ´Ï¸ç, Ãß°¡ÀûÀ¸·Î ¾÷µ¥ÀÌÆ®µÇ°Å³ª ¼öÁ¤µÉ ¼ö ÀÖ½À´Ï´Ù. |
| * |
º¹¾àÀ̹ÌÁöÀÇ Ç¥½Ã¿©ºÎ´Â ½ÇÁ¦ ¾à¹°º¹¿ë½Ã Á߿䵵¿¡ µû¸¥°ÍÀº ¾Æ´Ï¸ç ´Ü¼øÈ÷ Çã°¡Á¤º¸»ó Ű¿öµå¸¦ ±âÁØÀ¸·Î µî·ÏµÇ¾ú½À´Ï´Ù. |
| * |
±ÍÇϰ¡ º¹¾àÀ̹ÌÁö Á¤º¸¸¦ ½Å·ÚÇÔÀº ÀüÀûÀ¸·Î ±ÍÇÏÀÇ Ã¥ÀÓÀÔ´Ï´Ù. µå·°ÀÎÆ÷´Â ÀÌ¿¡ ´ëÇÑ ¾î¶°ÇÑ º¸Áõµµ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Diphenylpyraline¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms.
|
| Pharmacology |
Diphenylpyraline¿¡ ´ëÇÑ Pharmacology Á¤º¸ Diphenylpyraline is an antihistamine that prevents, but does not reverse, responses mediated by histamine alone. Diphenylpyraline antagonizes most of the pharmacological effects of histamine, including urticaria and pruritus. Also, diphenylpyraline may exhibit anticholinergic actions (as do most of the antihistamines) and may thus provide a drying effect on the nasal mucosa.
|
| Protein Binding |
Diphenylpyraline¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ > 99% in human serum albumin
|
| Half-life |
Diphenylpyraline¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Diphenylpyraline¿¡ ´ëÇÑ Absorption Á¤º¸ Well absorbed after oral administration.
|
| Biotransformation |
Diphenylpyraline¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
|
| Toxicity |
Diphenylpyraline¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Diphenylpyraline¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Diphenylpyraline¿¡ ´ëÇÑ Description Á¤º¸ Diphenylpyraline is an antihistamine. Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells. Antihistamines prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus.
|
| Dosage Form |
Diphenylpyraline¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntradermalLiquid Subcutaneous
|
| Drug Category |
Diphenylpyraline¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihistamines
|
| Smiles String Canonical |
Diphenylpyraline¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
|
| Smiles String Isomeric |
Diphenylpyraline¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
|
| InChI Identifier |
Diphenylpyraline¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C19H23NO/c1-20-14-12-18(13-15-20)21-19(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-19H,12-15H2,1H3
|
| Chemical IUPAC Name |
Diphenylpyraline¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 4-[di(phenyl)methoxy]-1-methylpiperidine
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2015-03-19
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|